Omicron Mutation – FDA: Green light for booster dose of Pfizer vaccine in 16 and 17 year olds

With the main goal of improving the protection against its Delta executive coronavirus which so far is the strain prevailing in USA, but also because of its imminent threat Omicron mutation, The FDA approved its aid installments vaccine the company’s Pfizer in people 16 and 17 years old, based on some data from South African scientists, who pointed out that the aid doses play a decisive role against the new strain.

The doctors of the Therapeutic Clinic of the Medical School of the National and Kapodistrian University of Athens Theodora Psaltopoulou, Panos Malandrakis, Giannis Danasis and Thanos Dimopoulos (Rector of EKPA) summarize the new data.

Aid doses have already been approved for adults over 18, and Moderna and Johnson vaccines are not approved for people under 18. The scientists concluded that the benefit of a continuous protection from a dose of aid exceeds the potential risk of rare side effects, especially in cases of myocarditis reported in young men. For children under 16 years, data on aid doses are not yet mature while children will probably be able to wait more than six months after completing their initial vaccination.

The Pfizer vaccine tested and in children under 5 years, has not yet received approval, but sufficient safety and efficacy data will be available in the first months of 2022. Parents, however, are skeptical about vaccinating young people and adolescents, especially in the 5-11 age group, as 16% of parents say their children at this age have received at least one dose, and 13% plan to vaccinate them immediately, while 30% clearly do not intend to vaccinate their children. According to the APE-MPE, the aid dose may be the answer to the new Omicron strain, as a new study by Pfizer showed that the aid dose in people over 16 years old reaches efficiency approaching 95%, in relation to those who did not receive it.